Cost of revenue · 2018–2019
Regeneron Pharmaceuticals cost of revenue
$403M+69.6% · FY2019
Regeneron Pharmaceuticals (REGN) reported $403M in cost of revenue for fiscal 2019, +69.6% year on year.
Cost of revenue — Cost of revenue is the direct cost of producing what the company sold — materials, manufacturing and the labour tied to delivery. It excludes sales, marketing and administration. Revenue minus this figure is gross profit.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2018–2019 compound annual growth +69.6%
Cost of revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Regeneron Pharmaceuticals cost of revenue |url=https://companiesranked.com/en/company/regeneron-pharmaceuticals/cost-of-revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Regeneron Pharmaceuticals cost of revenue. CompaniesRanked. https://companiesranked.com/en/company/regeneron-pharmaceuticals/cost-of-revenueBibTeX
@misc{companiesranked-en-company-regeneron-pharmaceuticals-cost-of-revenue-2026,
author = {{CompaniesRanked}},
title = {{Regeneron Pharmaceuticals cost of revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/regeneron-pharmaceuticals/cost-of-revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.